Key facts
- It has raised $500K; the latest was Early Stage VC in Jun 2025.
- Notable investors include Y Combinator, BoxGroup, SV Angel, CRV.
- Status: Privately Held (backing).
Investors
4- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Reticular
- ·The full record, as it builds
Funding rounds
No funding rounds for Reticular are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Reticular
Developer of AI-powered interpretability tools intended for biological AI systems. The company's research focuses on developing methods to understand and control the decision-making processes of biological AI models, particularly in protein engineering, enabling researchers and developers to build reliable and predictable AI systems for drug discovery and other bioengineering applications.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2024
- Employees
- 3
- Website
- reticular.ai/
- Ownership
- Privately Held (backing)
Reticular doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Reticular shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Reticular in its N-PORT filings yet. We sweep new filings monthly.